Merck


Electronics came as a big surprise

15/05/24 -"Merck started the year well, with Electronics being the largest contributor, demonstrating organic sales growth after several stagnant quarters. Healthcare also posted robust top-line growth and even ..."

Pages
67
Language
English
Published on
15/05/24
You may also be interested by these reports :
10/07/26
Astra’s cardiovascular drug, Wainua, failed a late-stage trial for a heart condition, and most of the drug’s $5bn peak sales expectations hinged on ...

07/07/26
Following the June 2026 phase III R&D setback for an investigational drug, Riliprubart, targeting a rare neurological disease called CIDP (chronic ...

06/07/26
Our target price has been adjusted downward as we have removed the 20% premium associated with peer-based valuation metrics. This adjustment is due ...

30/06/26
The recent US Supreme Court decision in the Roundup litigations, went in favour of Bayer, and brings the firm very close to ending this chapter. Even ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO